Ratings hVIVO plc

Equities

VENN

GB00B9275X97

Market Closed - London S.E. Other stock markets 11:35:27 2024-06-28 EDT			5-day change	1st Jan Change
26.95 ^GBX	-.--%		-1.28%	+13.47%

06-03	HVIVO says Omicron contract validates move to Canary Wharf facility	AN
06-03	HVIVO plc Signs £2.5 Million Contract with A Mid-Sized Pharmaceutical Company to Initiate an Omicron characterization study	CI

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

Strengths

Thanks to a sound financial situation, the firm has significant leeway for investment.
For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
Analysts covering this company mostly recommend stock overweighting or purchase.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Over the past four months, analysts' average price target has been revised upwards significantly.
Analyst opinion has improved significantly over the past four months.

Weaknesses

The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
The company benefits from high valuations in earnings multiples.
The company appears highly valued given the size of its balance sheet.
The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
HVIVO PLC	+13.47%	232M	-
MODERNA, INC.	+19.41%	45.51B	B-
IQVIA HOLDINGS INC.	-8.62%	38.52B	B
LONZA GROUP AG	+38.65%	38.13B	A
ALNYLAM PHARMACEUTICALS, INC.	+26.95%	30.74B	B
CELLTRION, INC.	-13.50%	26.03B	C
ICON PUBLIC LIMITED COMPANY	+10.74%	25.92B	B-
UNITED THERAPEUTICS CORPORATION	+44.87%	14.13B	B+
MEDPACE HOLDINGS, INC.	+34.36%	12.73B	C+
BIO-TECHNE CORPORATION	-7.14%	11.29B	B+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes